NIA's Top Crypto, Psychedelic, and Overall Picks for 2021

NIA's #1 favorite cryptocurrency pick and #2 overall stock suggestion for 2021 is CurrencyWorks (TSXV: CWRK), currently $0.16 per shareNIA's #1 favorite psychedelic pick and #1 overall stock suggestion for 2021 is BetterLife Pharma (CSE: BETR) or BETRF on the U.S. OTCQB, currently $1.25 per share.

CWRK has 34,926,033 shares outstanding for a market cap of US$4.89 million. CWRK creates digital currencies for brands. CWRK is redefining the transaction value chain for customer attraction, engagement and retention for brands by increasing transactions through the creation and implementation of their own digital currency.

This past Wednesday, CWRK released huge news that went unnoticed by the investment community. CWRK in partnership with the Canadian Securities Exchange (CSE) and Odyssey Trust Company announced the development of a security token reporting system that can be immediately deployed to drive value for public issuers.

A unique security token can be associated with each issuer on the CSE that opts into the platform, enabling Odyssey Trust to provide issuers with deeper reporting information and enhanced transfer agent services. The blockchain reporting system will run parallel to the existing clearing and settlement services for CSE issuers.

CWRK will provide various integration services, as well as testnet and smart contract platforms. These will be used to test and validate the process of issuing security tokens.

The security tokens will provide issuers and investors with an innovative way to create value and liquidity. They will allow resource companies to raise capital by utilizing their reserves, or future sales, without diluting their current equity. Any company with a recurring revenue model will find security tokens very appealing.

According to Richard Carleton, CEO of the CSE, "The CSE is committed to leading international exchange markets in the listing and trading of regulated security tokens, and we are pleased to be collaborating with CurrencyWorks and Odyssey Trust to support the infrastructure enabling security token offerings in Canada. We have seen tremendous interest in security tokens among both existing and potential CSE issuers."

BETR announced this morning that it has closed on the acquisition of the psychedelic company Transcend Biodynamics LLC, a research driven biotechnology company committed to addressing unmet mental health needs through the development of patented next generation psychedelic therapeutics including the Lysergic Acid Diethylamide (LSD) derivative BOL-148.

BOL-148 is a nontoxic second-generation LSD-derived molecule that mimics the therapeutic potential of LSD, without the hallucinations. BETR's patented process allows for cost-effective manufacturing of BOL-148 without the need to make LSD. This makes BETR the only entity with the ability to synthesize BOL-148 without the regulatory hurdles of handling a Schedule 1 controlled substance.

BOL-148 is also known as 2-Bromo-LSD and BETR's patented process is called, "Process of synthesizing 2-bromo-lsd". You can see BETR's U.S. patent for yourself by clicking here. The original U.S. Provisional Patent Application was filed nearly six years ago on January 8, 2015 at a time when almost nobody was interested in the legal production of psychedelic drugs. The patent doesn't expire until January 7, 2036.

Back on July 20, 2020, NIA announced BETR at $1.89 per share as its #1 favorite COVID-19 treatment play. On July 23, 2020, BETR hit a high of $2.90 per share for a four-day gain of 53.44%. NIA suggested BETR after Synairgen (SNG.L) gained by 456% in a single day on news of positive results from its clinical trial of SNG001, an inhaled formulation of interferon beta, in hospitalised COVID-19 patients. BETR has its own COVID-19 therapeutic called AP-003, an inhaled formulation of interferon alpha 2b (IFNa2b). BETR's AP-003 inhalation applies INFa2b directly to the lungs which may enable infected cells to halt viral replicationAP-003 inhalation may help to restore the initial immune response to COVID-19. Reports over the weekend of a new more contagious strain of COVID-19 will create renewed interest in COVID-19 therapeutics.

Past performance is not an indicator of future returns. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. NIA has not been compensated by CWRK but the CEO of CWRK is also the CEO of DFLY and NIA has received compensation from DFLY of USD$30,000 cash for a six-month marketing contract. NIA has received compensation from BETR of USD$50,000 cash and expects to receive an additional USD$50,000 worth of restricted BETR shares for a six-month marketing contract. NIA previously received compensation from BETR of USD$50,000 cash for a six-month marketing contract which has since expired. This message is meant for informational and educational purposes only and does not provide investment advice.